Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lamvik

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
European Journal of Haematology|August 1, 1997
Survival in 86 patients, aged 15-60, with primary acute myelogenous leukemia, treated with a common program in the Norwegian health regions I, III, IV and V in the period 1990-1995J M Tangen, M Abdelnoor, L Brinch, et al.
Scandinavian Journal of Haematology|September 1, 1986
Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapyO Kildahl-Andersen, P Bjark, A Bondevik, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 25, 1999
[Chronic myeloid leukemia in health regions 1, 3, 4 and 5 during the period 1990-96]J Lamvik, L Brinch, I M Dahl, et al.
Clinical Immunology and Immunopathology|October 1, 1991
Cytokine-associated tissue injury and lethality in mice: a comparative studyM R Shalaby, J Halgunset, O A Haugen, et al.
Medical Oncology (Northwood, London, England)|January 10, 2002
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell supportN Gulbrandsen, F Wisløff, L Brinch, et al.
Blood|December 23, 1999
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study GroupS Lenhoff, M Hjorth, E Holmberg, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
European Journal of Haematology|August 1, 1997
Survival in 86 patients, aged 15-60, with primary acute myelogenous leukemia, treated with a common program in the Norwegian health regions I, III, IV and V in the period 1990-1995J M Tangen, M Abdelnoor, L Brinch, et al.
Scandinavian Journal of Haematology|September 1, 1986
Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapyO Kildahl-Andersen, P Bjark, A Bondevik, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 25, 1999
[Chronic myeloid leukemia in health regions 1, 3, 4 and 5 during the period 1990-96]J Lamvik, L Brinch, I M Dahl, et al.
Clinical Immunology and Immunopathology|October 1, 1991
Cytokine-associated tissue injury and lethality in mice: a comparative studyM R Shalaby, J Halgunset, O A Haugen, et al.
Medical Oncology (Northwood, London, England)|January 10, 2002
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell supportN Gulbrandsen, F Wisløff, L Brinch, et al.
Blood|December 23, 1999
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study GroupS Lenhoff, M Hjorth, E Holmberg, et al.
Pageof 5